Growth through acquisition is an SOP for the biopharmaceutical industry. Once a deal is done, however, the hard work of operational integration and quality management is essential for realizing the expected benefits.
In early 2016, a company based in Lexington, Massachusetts acquired an established GMP antibody manufacturing pilot plant in Berkley, California. It was a strategic acquisition that added important capacity to make antibodies for the Lexington company’s growing immuno-oncology clinical programs.
The acquired plant’s experienced chemistry, manufacturing, and controls (CMC) team remained with the merged company to operate the facility and adapt their processes to support new programs.